AeroCentury Corp. (ACY) Reaches $12.40 52-Week High, Maverick Capital LTD Has Upped Insys Therapeutics New (INSY) Position

June 19, 2017 - By Ellis Scott

The stock of AeroCentury Corp. (NYSEMKT:ACY) hit a new 52-week high and has $13.39 target or 8.00% above today’s $12.40 share price. The 8 months bullish chart indicates low risk for the $17.78M company. The 1-year high was reported on Jun, 19 by Barchart.com. If the $13.39 price target is reached, the company will be worth $1.42M more. It is 0.00% or $0 reaching $12.4 per share. It is down 23.55% since June 19, 2016 and is downtrending. It has underperformed by 40.25% the S&P500.

Maverick Capital Ltd increased Insys Therapeutics Inc New (INSY) stake by 34.51% reported in 2016Q4 SEC filing. Maverick Capital Ltd acquired 70,351 shares as Insys Therapeutics Inc New (INSY)’s stock rose 13.42%. The Maverick Capital Ltd holds 274,211 shares with $2.52M value, up from 203,860 last quarter. Insys Therapeutics Inc New now has $821.50M valuation. The stock rose 0.71% or $0.08 reaching $11.4 per share. About 33,137 shares traded. Insys Therapeutics Inc (NASDAQ:INSY) has declined 5.69% since June 19, 2016 and is downtrending. It has underperformed by 22.39% the S&P500.

AeroCentury Corp. acquires used regional aircraft and aircraft engines for lease to regional carriers all over the world. The company has market cap of $17.78 million. The Company’s segment is leasing of regional aircraft to foreign and domestic regional airlines. It has a 13.52 P/E ratio. The business of the Company is managed by JetFleet Management Corp. , an integrated aircraft management, marketing and financing business.

Investors sentiment increased to 2 in 2016 Q4. Its up 1.50, from 0.5 in 2016Q3. It improved, as 1 investors sold AeroCentury Corp. shares while 1 reduced holdings. 1 funds opened positions while 3 raised stakes. 217,623 shares or 7.13% more from 203,135 shares in 2016Q3 were reported. Moreover, Tower Research Limited Liability Corp (Trc) has 0% invested in AeroCentury Corp. (NYSEMKT:ACY) for 221 shares. Manufacturers Life Insurance Company The reported 0% in AeroCentury Corp. (NYSEMKT:ACY). Renaissance Tech Llc holds 16,700 shares or 0% of its portfolio. Dimensional Fund Advsr Ltd Partnership accumulated 75,714 shares or 0% of the stock. Blackrock Fund Advsrs owns 249 shares. Perritt Mngmt Inc accumulated 34,047 shares. Bridgeway Mgmt Incorporated reported 21,000 shares. 54,597 were reported by Leisure Management. Grt Cap Prtnrs Ltd reported 0.04% stake. Federated Inc Pa invested 0% in AeroCentury Corp. (NYSEMKT:ACY).

Since May 16, 2017, it had 4 insider buys, and 0 insider sales for $268,142 activity. Motahari Saeed bought $59,955 worth of stock or 5,400 shares. Shares for $56,575 were bought by Vishnoi Rohit. The insider MEYER STEVEN J bought $97,680.

Among 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Insys Therapeutics had 11 analyst reports since August 4, 2015 according to SRatingsIntel. The company was maintained on Tuesday, August 4 by Oppenheimer. The rating was maintained by Jefferies with “Buy” on Wednesday, February 24. The stock of Insys Therapeutics Inc (NASDAQ:INSY) has “Buy” rating given on Tuesday, April 12 by Jefferies. The stock of Insys Therapeutics Inc (NASDAQ:INSY) earned “Buy” rating by Jefferies on Thursday, August 4. The firm earned “Buy” rating on Monday, October 10 by Jefferies. The stock has “Buy” rating by Janney Capital on Thursday, April 14. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, December 21. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, September 22. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, June 1. The stock of Insys Therapeutics Inc (NASDAQ:INSY) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9.

Maverick Capital Ltd decreased Navient Corp (NASDAQ:NAVI) stake by 28,540 shares to 189,750 valued at $3.12 million in 2016Q4. It also reduced Commscope Hldg Co Inc (NASDAQ:COMM) stake by 6.47M shares and now owns 10.03M shares. United Contl Hldgs Inc (NYSE:UAL) was reduced too.

Investors sentiment decreased to 0.86 in Q4 2016. Its down 0.37, from 1.23 in 2016Q3. It fall, as 21 investors sold INSY shares while 43 reduced holdings. 21 funds opened positions while 34 raised stakes. 27.44 million shares or 9.45% less from 30.31 million shares in 2016Q3 were reported. Eqis Mngmt holds 0.04% or 73,193 shares in its portfolio. Moreover, Bank & Trust Of Montreal Can has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 6,600 shares. Next Fincl Gru reported 1,815 shares. Panagora Asset Mngmt reported 1,359 shares. Bnp Paribas Arbitrage Sa stated it has 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Tiaa Cref Inv Limited Liability Corp holds 0% or 64,208 shares in its portfolio. Dupont Capital reported 36,606 shares or 0.01% of all its holdings. 150 are held by Ogorek Anthony Joseph Ny Adv. Renaissance Technologies Ltd Liability, New York-based fund reported 241,500 shares. Ascend Capital Ltd Liability Corporation has 225,000 shares. Private Ocean Ltd Liability has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 130 shares. Schneider Capital Mgmt Corporation reported 0.07% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). New York State Common Retirement Fund holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 22,700 shares. National Bank Of America De holds 0% or 126,636 shares in its portfolio. Blackrock Mngmt Ltd Liability invested 0% in Insys Therapeutics Inc (NASDAQ:INSY).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: